The Food and Drug Administration (FDA) has received 25 reports linked to recalled NAN OPTIPRO and NANKID OPTIPRO infant formula products, with 18 involving health concerns observed by parents or caregivers after consumption.

In an advisory on January 16, the FDA said that “as of 15 January 2026, the FDA has received twenty-five (25) reports associated with the recalled products,” adding that “eighteen (18) of these reports involve health concerns observed by parents or caregivers following consumption of the subject infant formula.”

According to the agency, reported symptoms included “vomiting, diarrhea, abdominal pain, and other conditions, some of which required medical attention.”

The FDA stressed that all complaints are undergoing evaluation to determine appropriate regulatory action.

“All reports received by the FDA are subject to review to determine the appropriate regulatory actions,” the agency stated.

“Each report is evaluated, and—when necessary—the FDA coordinates with relevant agencies and offices to ensure proper handling, verification, and resolution of the reported concerns.”

The FDA said it remains in close coordination with the market authorization holder, Nestlé Philippines, Inc., which has been directed to regularly submit updates on the status and progress of the voluntary recall.

“The FDA continues to maintain close regulatory coordination with the Market Authorization Holder, Nestlé Philippines, Inc., which has been directed to submit regular and timely status reports on the implementation, assessment, and progress of the voluntary recall,” it said.

The agency added that systems are already in place to process and assess consumer complaints, including suspected adverse events, and that the recall is being monitored through post-market surveillance.

“Established procedures remain in place for the receipt, documentation, assessment, and appropriate disposition of consumer complaints, including reports of suspected adverse events,” the advisory read.

Amid growing concern among parents, the FDA urged caregivers to closely monitor their children’s health and seek medical advice when necessary.

“The FDA understands the concerns of parents and caregivers and encourages them to continue closely caring for and observing the well-being of their infants and young children,” it said.

“Should there be any concerns about a child’s health, seeking advice from a healthcare professional is encouraged.”

The agency also encouraged the public to report related concerns to [email protected] to help authorities monitor the situation.